Insiders · VYNE

VYNE insider transactions

VYNE Therapeutics Inc. (VYNE) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for VYNE

• 26d
  Large owner Rtw Fund Group Gp, Llc disposed of 133,290 shares (SEC Form 4)

  4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 26d
  New insider Rtw Fund Group Gp, Llc claimed ownership of 399,597 shares (SEC Form 3)

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 4 filed by Director Ashiya Mona

  4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 4 filed by Director Zeronda Tyler

  4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  New insider Orbimed Advisors Llc claimed ownership of 266,306 shares (SEC Form 3)

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  New insider Ashiya Mona claimed ownership of 266,306 shares (SEC Form 3)

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider White William Richard

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Silverman Peter B.

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Lundberg Sven Ante

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Hoerter Steven L.

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Alford Rachael

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Payton Lori

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Ryder Steven

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  SEC Form 3 filed by new insider Frey Rebecca

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 27d
  New insider Perceptive Advisors Llc claimed ownership of 266,309 shares (SEC Form 3)

  3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
• 32d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 23% to 74,918 units (SEC Form 4) (withholding obligation)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 32d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 15,405 shares, decreasing direct ownership by 14% to 95,944 units (SEC Form 4) to cover taxes

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 32d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 79,391 shares, decreasing direct ownership by 19% to 347,174 units (SEC Form 4) (for tax liability)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 32d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 19% to 95,918 units (SEC Form 4) to satisfy withholding tax

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 54d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,464 shares, decreasing direct ownership by 3% to 118,434 units (SEC Form 4) (for tax liability)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 54d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,214 shares, decreasing direct ownership by 3% to 426,565 units (SEC Form 4) (tax liability)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 54d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 2% to 111,349 units (SEC Form 4) (tax withholding)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 54d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,464 shares, decreasing direct ownership by 3% to 97,434 units (SEC Form 4) to cover taxes

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 84d
  PRESIDENT AND CEO Domzalski David was granted 30,791 shares, increasing direct ownership by 8% to 438,779 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 145d
  SEC Form 4 filed by Zeronda Tyler

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 145d
  SEC Form 4 filed by Stuart Iain

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 145d
  SEC Form 4 filed by Harsch Mutya

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 145d
  SEC Form 4 filed by Domzalski David

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 232d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,684 shares, decreasing direct ownership by 3% to 416,208 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 232d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,448 shares, decreasing direct ownership by 2% to 115,239 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 232d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 7,858 shares, decreasing direct ownership by 7% to 103,795 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 232d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,579 shares, decreasing direct ownership by 3% to 125,905 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 253d
  SEC Form 4 filed by Director Barbari Sharon

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 253d
  SEC Form 4 filed by Director Basta Steven L

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 253d
  SEC Form 4 filed by Director Little Elisabeth Sandoval

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 253d
  SEC Form 4 filed by Director Lepore Patrick G

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 327d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,453 shares, decreasing direct ownership by 2% to 117,687 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 327d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,676 shares, decreasing direct ownership by 3% to 428,892 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 327d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,420 shares, decreasing direct ownership by 3% to 111,653 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 327d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,581 shares, decreasing direct ownership by 3% to 129,484 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 419d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,420 shares, decreasing direct ownership by 3% to 115,073 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 419d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,453 shares, decreasing direct ownership by 2% to 120,140 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 419d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,581 shares, decreasing direct ownership by 3% to 133,065 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 419d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,676 shares, decreasing direct ownership by 3% to 441,568 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 448d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya was granted 1,145 shares, increasing direct ownership by 0.85% to 136,646 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 448d
  PRESIDENT AND CEO Domzalski David was granted 8,681 shares, increasing direct ownership by 2% to 454,244 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 510d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 8,399 shares, decreasing direct ownership by 7% to 118,493 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 510d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 6,044 shares, decreasing direct ownership by 5% to 122,593 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 510d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 8,828 shares, decreasing direct ownership by 6% to 135,501 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 510d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 30,498 shares, decreasing direct ownership by 6% to 445,563 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 579d
  SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Stuart Iain

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 579d
  SEC Form 4 filed by CHIEF FINANCIAL OFFICER Zeronda Tyler

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 579d
  SEC Form 4 filed by CHIEF LEGAL OFFICER AND GC Harsch Mutya

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 579d
  SEC Form 4 filed by PRESIDENT AND CEO Domzalski David

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 586d
  Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 600d
  CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 4,857 shares, decreasing direct ownership by 4% to 128,637 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 600d
  CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 4,675 shares, decreasing direct ownership by 4% to 126,892 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 600d
  PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 24,536 shares, decreasing direct ownership by 5% to 476,061 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 600d
  CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 4,697 shares, decreasing direct ownership by 3% to 144,329 units (SEC Form 4)

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
• 620d
  SEC Form 4 filed by Director Borowski Christine

  4 - VYNE Therapeutics Inc. (0001566044) (Issuer)